Merus N.V. (MRUS): Price and Financial Metrics


Merus N.V. (MRUS)

Today's Latest Price: $25.19 USD

0.16 (0.64%)

Updated Jan 21 1:31pm

Add MRUS to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 484 in Biotech

See all "A" rated Strong Buy stocks

MRUS Stock Summary

  • For MRUS, its debt to operating expenses ratio is greater than that reported by just 7.49% of US equities we're observing.
  • With a price/sales ratio of 25.53, Merus NV has a higher such ratio than 91.11% of stocks in our set.
  • Over the past twelve months, MRUS has reported earnings growth of 196.5%, putting it ahead of 92.8% of US stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Merus NV are SNSS, SILC, ONCT, FPRX, and AKBA.
  • Visit MRUS's SEC page to see the company's official filings. To visit the company's web site, go to www.merus.nl.

MRUS Stock Price Chart Interactive Chart >

Price chart for MRUS

MRUS Price/Volume Stats

Current price $25.19 52-week high $26.80
Prev. close $25.03 52-week low $10.18
Day low $24.90 Volume 768,564
Day high $26.58 Avg. volume 203,251
50-day MA $17.50 Dividend yield N/A
200-day MA $14.56 Market Cap 732.75M

Merus N.V. (MRUS) Company Bio


Merus B.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. The company was founded in 2003 and is based in Utrecht, Netherlands.


MRUS Latest News Stream


Event/Time News Detail
Loading, please wait...

MRUS Latest Social Stream


Loading social stream, please wait...

View Full MRUS Social Stream

Latest MRUS News From Around the Web

Below are the latest news stories about Merus NV that investors may wish to consider to help them evaluate MRUS as an investment opportunity.

Lilly signs cancer drug deal worth up to $1.6 billion

Shares of Eli Lilly & Co. gained 0.8% in premarket trading on Wednesday, the day after the drugmaker announced a deal worth up to $1.6 billion with Merus to develop three antibody therapies aimed at treating cancer. The Dutch company's stock was down 5.1% in premarket trading on Wednesday. The deal, which includes research and a licensing agreement, is designed to give Merus an upfront payment of $40 million, a $20 million equity investment, and up to $540 million in potential milestone payments. Over the last year, Lilly's stock has gained 42.2%, shares of Merus are up 45.5%, and the S&P 500 has rallied 14.5%.

Yahoo | January 20, 2021

The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study

Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 19) * 4D Molecular Therapeutics Inc (NASDAQ: FDMT) * ABIOMED, Inc. (NASDAQ: ABMD) * AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) * Aclaris Therapeutics Inc (NASDAQ: ACRS) ( reacted to a positive mid-stage readout) * Adaptive Biotechnologies Corp (NASDAQ: ADPT) * Akari Therapeutics PLC (NASDAQ: AKTX) * Aldeyra Therapeutics Inc (NASDAQ: ALDX) * Alkermes Plc (NASDAQ: ALKS) * Apyx Medical Corp (NASDAQ: APYX) * Arvinas Inc (NASDAQ: ARVN) * Beigene Ltd (NASDAQ: BGNE) * Bicycle Therapeutics PLC (NASDAQ: BCYC) * BIO-TECHNE Corp (NASDAQ: TECH) * BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) * Biodesix Inc (NASDAQ: BDSX) * BioNano Genomics Inc...

Yahoo | January 20, 2021

Lilly (LLY) Inks Deal With Merus to Discover Cancer Antibodies

Eli Lilly (LLY) signs a deal with Merus to develop novel T-cell re-directing bispecific antibodies. While Merus will lead early-stage development, Loxo Oncology will take care of further development and commercialization.

Yahoo | January 20, 2021

Merus N.V. Announces Proposed Public Offering of Common Shares

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we” and “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics™), today announced the launch of a proposed underwritten public offering of up to $60 million of its common shares. All of the common shares are being offered by Merus. In addition, Merus expects to grant the underwriters a 30-day option to purchase up to an additional $9 million of its common shares. The offering is subject to market conditions and other closing conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Merus intends to use the net p...

Yahoo | January 19, 2021

Lilly and Merus NV Announce Collaboration to Discover Novel T-Cell Re-Directing Bispecific Antibodies

Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and Merus N.V. (NASDAQ: MRUS), a clinical-stage oncology company developing multi-specific antibodies, today announced a research collaboration and exclusive license agreement that will leverage Merus' proprietary Biclonics® platform along with the scientific and rational drug design expertise of Loxo Oncology at Lilly to research and develop up to three CD3-engaging T-cell re-directing bispecific antibody therapies.

Yahoo | January 19, 2021

Read More 'MRUS' Stories Here

MRUS Price Returns

1-mo 47.74%
3-mo 92.88%
6-mo 86.87%
1-year 47.22%
3-year 34.49%
5-year N/A
YTD 43.70%
2020 24.50%
2019 0.57%
2018 -27.84%
2017 -8.10%
2016 N/A

Continue Researching MRUS

Want to see what other sources are saying about Merus NV's financials and stock price? Try the links below:

Merus NV (MRUS) Stock Price | Nasdaq
Merus NV (MRUS) Stock Quote, History and News - Yahoo Finance
Merus NV (MRUS) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.9154 seconds.